Charles River Laboratories | CRL - Nettoeinkommen

Aktienkurs
166.79
Täglich Wechseln
-4.44 -2.59%
Monatlich
4.43%
Jährlich
42.20%
Q2 Prognose
166.17




Nettoeinkommen Veränderung Datum
Agilent USD 305M 129M 2025-12
Align Technology USD 135.76M 79.01M 2025-12
Bio-Rad Laboratories USD -341.9M 659.7M 2025-09
Bruker USD 26M 88.4M 2025-12
Cardinal Health USD 467M 17M 2025-12
Charles River Laboratories USD -276.56M 330.98M 2025-12
Cigna USD 1.23B 55.22B 2025-12
Concord Medical Services Hldg CNY -27.14M 63.85M 2025-06
CVS Health USD 2.94B 6.92B 2025-12
Danaher USD 1.03B 168M 2026-03
Dentsply International USD -146M 281M 2025-12
Elevance Health USD 1.76B 1.22B 2026-03
Galapagos EUR 782.15M 984.26M 2025-12
Humana USD -796M 991M 2025-12
Illumina USD 334M 184M 2025-12
Incyte USD 299.28M 124.89M 2025-12
IQVIA Holdings USD 514M 183M 2025-12
Laboratory Of America USD 164.7M 96.4M 2025-12
Lonza CHF 426M 119M 2025-06
McKesson USD 1.19B 76M 2025-12
Merck EUR 319M 583M 2025-12
Mettler Toledo International USD 285.76M 68.27M 2025-12
Novartis USD 2.41B 1.52B 2025-12
Pfizer USD -1.65B 5.19B 2025-12
Quest Diagnostics USD 251M 6M 2026-03
Revvity USD 98.36M 51.71M 2025-12
Thermo Fisher Scientific USD 1.65B 313M 2026-03
United Therapeutics USD 364.3M 25.6M 2025-12
UnitedHealth USD 6.28B 6.27B 2026-03
Veradigm USD -59.82M 74.35M 2022-12
Waters USD 225.21M 76.29M 2025-12
West Pharmaceutical Services USD 138.8M 6.7M 2026-03